Australian (ASX) Stock Market Forum

MBP - Metabolic Pharmaceuticals

Status
Not open for further replies.
Shish I'm a lucky bleeder.....got back in @ 75 cents mighty proud to the fact CIR dumped their shares onto the market ........
since the close of trade on friday last week this share has shown great resistance around the 80~84 cents circa ........so if anybody picked a few up today I think we can thank CIR.......

30 November 2006
The Companies Section
The Australian Stock Exchange Limited
530 Collins Street
MELBOURNE VIC 3000
Dear Sir/Madam
Change in Substantial Holding for Metabolic Pharmaceuticals Limited
We enclose Form 604 being a Notice of Change of Interests of Substantial Holder by
Polychip Pharmaceuticals Pty Ltd (Polychip), a wholly owned subsidiary of Circadian Technologies
Limited.
The Notice of Change is in reference to the sale by Polychip of 12,000,000 ordinary shares in Metabolic
Pharmaceuticals Limited (Metabolic) on 29 November 2006 to institutional investors. Polychip’s interest
in Metabolic has as such decreased from 16.87% (being Polychip’s interest immediately before the sale)
to 12.66% representing a holding of 36,012,701 shares.
Yours sincerely
Natalie Korchev
Company Secretary
Level 1, 10 Wallace Avenue,
Toorak, Victoria 3142, Australia
P: +61 (3) 9826 0399
Circadian Technologies Limited F: +61 (3) 9824 0083
ABN 32 006 340 567 www.circadian.com.au
FORM 604
Corporations Act 2001
Section 671B
NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER
 
News of a 'new discovery' of a toxin from a sea snail discovered by Dr. Jenny Ekberg and colleagues at the University of Queensland, has been getting a bit of a splash around the place.
But hasn't MBP been working on this now for a year or so? Mbp are even in Phase 2 human clinical tests.
The sea snail that Mbp discovered its toxin from, was the Conus Victoriea. The 'newly discovered toxin' found by Dr. Jenny Ekberg and colleagues at the University of Queensland is from the Conus Marmoreus, virtually the same sea snail.
Maybe Mbp are helping with the research there, but it sounds a bit like plagiarism.
I may have missed something here and Mbp may be tied up but I have not heard there name tied up with this new discovery?

http://www.medgadget.com/archives/2006/12/novel_anestheti.html

:confused:
'Novel Anesthetic Discovered in Sea Snail
Filed under: Anesthesiology , Pain



Dr. Jenny Ekberg and colleagues at the University of Queensland have discovered that a toxin from marine snail Conus marmoreus has interesting analgesic properties, similar to local anesthetics but without any motor blockade.

From the interview Dr. Ekberg gave to the press office of University of Queensland:

"The patient experiences severe pain because their nerve cells that are responsible for pain transmission are overactive," she said.
"This is primarily due to abnormal activity of voltage-gated sodium channels in the nerve cells.

"Conventional drugs, such as local anaesthetics, block all types of sodium channels, causing severe side-effects.

"Our toxin only blocks a specific channel -- the first time a toxin like this has been shown to work-- therefore providing pain relief without severe side-effects." '
 
This one doing its thing today ... I've taken the last of my long positions ... heavy relative volume and up 8% as I type ... if it can close at 90+ then this will be the signal for the next leg up
 
Closed up at 100 today again on heavy volume ... no announcements as yet ... does anyone have any insights?
 
This stock still climbing on expectations of results of double blinded 2b trial for obesity (also same drug for obesity is showing very good results for treating osteoporisis, with abilty to fasttrack due to efficacey and safety shown already)- but they have other products in the pipline in their back pocket. Novel platform that enables traditional therapies delivered by injection to be delivered orally - diabeties etc. They also have drug developing via venomous cone snail for pain relief as already mentioned by previous poster. Also in collarboration with Nuren Pharm. This company is maturing nicely. Positon: I hold and have been watching for approx 3 years.
 
Just have comeback from holiday with family ,and I have been suprised to see this share slide to todays levels .....does anybody following this share have any notions in what's causing the slide ,or is it just a case of traders moving on.......
From memory is there going to be an annoucement in March 07 re: recent trails being conducted???????
 
Well news is MBP will have repesentation on abc/tv Catalyst programme this thursday.... :D ,and how all the sellers of this share got snookered thinking the results might be out possibly by 7 march and they could pick up a bargain in a few weeks.
Anyway Dutchy if your still out there ,I hope your grinning like me :D
 
Whatever the outcome Dutchy,I have this radiation glow around my body,I will either vapourise ,or celebrate.....time to get emotional! :p:
 
Hi 3 and Dutchy, I've been following for years and have some in. This really does seem to be the most critical trading halt. My understanding is that they will be shooting to release by trade open tomorrow morning (Wed), otherwise asx open trade automatically for them. A rare event. I cant imagine its anything other than the results come earlier than March. Interesting that catalyst seem to be running story (I cant confirm this), they must have put it together ages ago - in any case I expect they will need to pull it if the results are negative ... and they cant legally know that yet, of course.
Stochastic
 
white monkey said:
Ann. out and it is all bad. This is not going to be pretty!

Feel bad for all the shareholders.....pretty ugly out there.....its the nature with biotech stocks.......if something goes wrong it goes horribly wrong. Thats the punt one takes and the drop in price in the lead up to trading halt could've been possibly insider knowledge of whats about to happen......

Poor punters......
 
No point flying the MBP flag today .To think that the results where due in soon ,and seeing the trading halt come into effect ,one could not be distracted that the share price was slipping .Just shows you insider info comes at premium.Very cuss dealings prior to trading halt.
As stated in my previous post I think I have vapourised. MBP is now trying to sell another scientific breakthrough,unfortunately I'm not going to buy their story I question their salesmanship.
Feel I should join the Bengal Lancers and charge down to the local pub to proclaim that obesisty lives on . Hope somebody shouts me a drink!
 
It is true that there are hundreds of small biotech companies like MBP.

If you read through their future drug pipeline.....all of these small caps read like the next CSL, however fast forward three years - and really nothing has changed. They are trying to make it big...but they usually never do.

Many investors considered MBP had their one chance at the making it into the big time also....with the weight loss drug. (We know what happened there. )

Exactly my views after after news of the obesity drug failure.......just as I was about sell at a big loss......decided to have a look at what other drugs they may have.

The more research that I did....the more interesting (the pain drug) seemed to become. Typical of the info that is out there on MBP's pain drug ACV1 is this from the inventor of the drug, before MBP secured the rights to it.
_________________________________________________________________

http://www.listserv.uga.edu/cgi-bin/wa?A2=ind0703b&L=conch-l&F=&S=&P=2759



Date: Sun, 11 Mar 2007 09:03:31 -0400
Reply-To: Conchologists List <CONCH-L@LISTSERV.UGA.EDU>
Sender: Conchologists List <CONCH-L@LISTSERV.UGA.EDU>
From: Livett Family <blivett@BIGPOND.NET.AU>
Subject: Update on Conus victoriae analgesic "ACV1"
Clincal trials (Phase 2A) of conotoxin Vc1.1 (ACV1) from Conus victoriae
were begun by Metabolic Pharmaceuticals, Melbourne, (www.metabolic.com.au)


ACV1 is a synthetic 16 amino acid peptide drug designed from a component
of the venom of the Australian marine cone snail, Conus victoriae, a
mollusc hunting cone shell.

In laboratory animals, ACV1 has profound, direct effects on pain sensing
nerves in the peripheral nervous system called C-fibres, which are
hypersensitive in neuropathic pain. It blocks a subtype of a broad class
of receptors called neuronal nicotinic acetylcholine receptors (nAChR)
which reside on the C-fibres. ACV1 has been shown to directly reduce the
sensitivity of sensitised C-fibres. It is the first drug to utilise this
biochemical mechanism.

ACV1 has been tested in several well-established animal pain models and
shows efficacy in relieving the characteristic pain symptoms of
neuropathy, allodynia and hyperalgesia, following subcutaneous or
intramuscular dosing. In addition, evidence suggests that ACV1 accelerates
the recovery of injured nerves and tissues.

On 24 November 2006, Metabolic Pharmaceuticals announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. This
programme involves two human clinical trials targeting specific
neuropathies. The first group of patients (with painful sciatica) in the
first of two trials in this Phase 2A programme have been treated and the
second trial (involving patients with painful shingles and others with
painful diabetic neuropathy) is due to commence in Q107. Additionally, a
separate trial to test safety of a higher dose level of ACV1 commenced in
Q406.


Enjoy !

Bruce Livett

_________________________________________________________________

As you can see from Dr Livett email....results are due soon for the phase trial 2 that started in Nov 2006. Little exclusive here where Dr Levitt reports that this trial is progressing well (this is a March email).

World market for this type of pain is increasing towards $5 billion. If successful....the drug will go a long way to replace morphine.
 
anyone have any idea for the large rise in the share price today and large increase in volume? possible news coming up?
 
Status
Not open for further replies.
Top